ArticleThe Journal of infectious diseases2016
Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- Comparison of Ebola virus infection routes and resulting disease in animal models.Journal of virology · 2026Review
- Recombinant Bombali ebolavirus in cynomolgus macaques as a survival model of Ebola virus disease.Nature communications · 2026Article
- The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.Science advances · 2025Article
- Filovirus vaccines as a response paradigm for emerging infectious diseases.NPJ vaccines · 2024Review
- An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.Expert opinion on drug discovery · 2024Review
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Hepatic and pulmonary macrophage activity in a mucosal challenge model of Ebola virus disease.Frontiers in immunology · 2024Article
- Ebola Virus Tropism in Ex Vivo Cynomolgus Macaque Ocular Tissues.The Journal of infectious diseases · 2023Article
- Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.The Journal of infectious diseases · 2023Article
- Characterization of Ebola Virus Mucosal Challenge Routes in Cynomolgus Macaques.Journal of virology · 2023Article
- Natural history of nonhuman primates after conjunctival exposure to Ebola virus.Scientific reports · 2023Article
- Role of Key Infectivity Parameters in the Transmission of Ebola Virus Makona in Macaques.The Journal of infectious diseases · 2022Article
- Macrophage infection, activation, and histopathological findings in ebolavirus infection.Frontiers in cellular and infection microbiology · 2022Review
- Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.Science translational medicine · 2021Article
- Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.EBioMedicine · 2019Article
- Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice.JCI insight · 2019Article
- Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model.Intensive care medicine experimental · 2019Article
- Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study.PLoS neglected tropical diseases · 2019Article
- Intramuscular Exposure ofViruses · 2018Article
- Modeling Ebola Virus Transmission Using Ferrets.mSphere · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Nonhuman primate (NHP) models of Ebola virus (EBOV) infection primarily use parenteral or aerosol routes of exposure. Uniform lethality can be achieved in these models at low doses of EBOV (≤100 plaque-forming units [PFU]). Here, we exposed NHPs to low doses of EBOV (Makona strain) by the oral or conjunctival routes. Surprisingly, animals exposed to 10 PFU by either route showed no signs of disease. Exposure to 100 PFU resulted in illness and/or lethal infection. These results suggest that these more natural routes require higher doses of EBOV to produce disease or that there may be differences between Makona and historical strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.